2. Step 2: After entering more functions, find the medical and health functions in the function list.
Step 3: Enter the medical health page and find more function buttons at the top of the page.
4. Step 4: Find the vaccine service after entering the medical care service.
5. Step 5, we directly find the hpv nine-price reservation in the lower left corner in the function list.
Operating environment: Alipay version 10.2.38.8200, mobile phone version: vivox27Andord5. 1.
I. Nine-valent HPV vaccine
Nine-valent HPV vaccine is used to prevent cervical cancer caused by human papillomavirus (HPV) infection, which can prevent more than 90% of cervical cancer. The vaccine was approved for marketing in the United States in 20 14. On April 28th, 20 18, the State Administration of Pharmaceutical Products conditionally approved the marketing of nine-valent HPV vaccine for preventing cervical cancer in China. Vaccination is primary prevention and screening is secondary prevention, both of which are equally important. Therefore, screening measures for cervical cancer cannot be relaxed because of vaccination.
Clinical significance of nine-valent HPV vaccine
Nine-valent HPV vaccine has good immunogenicity. After three doses of inoculation, the positive conversion rate of serum antibodies of related types can almost reach 100%. After vaccination 1 month, the peak geometric average titer of antibody can reach 100 times of the antibody level after natural infection, and this value will drop to 10 times in the next two months, and will remain in the platform period. The antibody level of the vaccine can be maintained for at least 4 years. In the clinical trial of the efficacy of the nine-valent HPV vaccine, the main end points are the persistent infection of related human papillomavirus type, genital warts of related human papillomavirus type, cervical intraepithelial neoplasia (CIN), external genital or vaginal intraepithelial neoplasia (VIN or VaIN). Clinical trials show that vaccination with nine-valent HPV vaccine can produce good protective effect, effectively reduce the persistent infection of corresponding types of human papillomavirus and precancerous lesions of cervix, vagina and external genitalia, and the protective effect can reach more than 90%. Nine-valent HPV vaccine contains human papillomavirus -6 and human papillomavirus-1 1 VLP, which has a good preventive effect on condyloma acuminatum.
Three, nine-valent human papillomavirus vaccination population
The age range of nine-valent HPV vaccine approved for marketing in China is 16-26-year-old women. The reason for this age group is from three aspects:
1. The clinical trial subjects supporting the marketing of this vaccine are16-26 year old women. At this age, the data of overseas clinical research and the protective effect of vaccines on persistent infection in East Asian people show that the advantages outweigh the disadvantages.
2. The probability of having sex with girls aged 9 ~ 15 in China is very low. Vaccinators aged 9 ~ 15 only carried out immune bridging test, and the clinical research data of East Asian Chinese population in this test were limited.
3. Women over the age of 26 may have a history of virus exposure and infection, but there is no evidence that this vaccine can protect the exposed population at this age.